Erin K. McCreary, PharmD (1), Ahmad Mourad, MD MHS (2, 3)

PREVENT aimed to evaluate the feasibility of a community self-swab respiratory surveillance system embedded within the FluTracking Australia Framework. Hig

ABSTRACTSubcutaneous delivery of antibiotics is a practical alternative to intravenous administration. Ceftriaxone is commonly used for a variety of infections with limited data on the safety and pharmacokinetics of a 2 g subcutaneous dose. This was a prospective, self-controlled cross-over study in 20 stable inpatients receiving ceftriaxone for their infection. Following an intravenous dose, participants received a single dose of 2 g subcutaneous ceftriaxone, in 50 mL normal saline via gravity feed. Capillary dried blood spots were collected at baseline, 1, 2, 4, 8, and 24 hours following the subcutaneous and intravenous doses. Pain scores and infusion site reactions (edema/erythema) were assessed. Ceftriaxone concentrations were measured using a validated liquid chromatography-tandem mass spectrometry assay. A population pharmacokinetic model was developed using nonlinear mixed-effects modeling. The highest median (interquartile range) pain score within the first 2 hours following infusion of a subcutaneous dose of 2 g ceftriaxone was 2.5 (1–4). All participants were pain-free 4 hours after the infusion. The estimated bioavailability was 95.7% (95% bootstrap interval 90.3–99.5). Compared with intravenous, subcutaneous administration resulted in lower peak and comparable trough concentrations. The probability of target attainment for free drug concentrations was similar to intravenous administration for most common infections in hospitalized patients. Subcutaneous administration of 2 g ceftriaxone is well tolerated and has a comparable pharmacokinetic profile relative to intravenous dosing in non-critically ill patients with severe infections.IMPORTANCEThis prospective, self-controlled cross-over design study demonstrates that subcutaneous administration of 2 g ceftriaxone appears safe and well tolerated with a comparable pharmacokinetic profile relative to intravenous dosing in non-critically ill patients with severe infections.CLINICAL TRIALSThis study was registered at ACTRN12624000692538.

Over the past two decades, the generation and application of clinical evidence in the fields of clinical infectious diseases and microbiology have entered a new era: one in which clinical guidelines a...

Hierarchical composite endpoints (HCEs) are increasingly being used in infectious diseases research. In this review aimed at educating the clinical reader,

Editors of CMI Comms, Josh Davis, Erin McCreary and Emily McDonald...

This episode of Communicable takes on a special format where editors of...

Podcast Episode · Breakpoints · 05/04/2025 · 1h 11m

More than hundred years ago a series of experiments demonstrated that increased strechting of heart muscles (through higher venous return) increased stroke volume (cardiac output). But not endlessly, ...

“Selective digestive tract decontamination” (SDD) refers to the use of antibiotics to decrease bacterial load in the gut with the intention of reducing the risk of pneumonia (from microaspiration) and...

For those who do hospital-based patient care, the significance of Staphylococcus aureus bacteremia (SAB) cannot be overstated. It’s one of the most frequent reasons for infectious disease consultation...

A major new clinical trial, the Streptococcal Adaptive Platform (STRAP), has received $5 million in funding from the Australian Government’s Medical Research Future Fund (MRFF) to improve treatment for life-threatening streptococcal infections across all age groups. Lead by researchers and clinicians from the Doherty Institute, Murdoch Children's Research Institute (MCRI), and other national and international partners.